These studies have demonstrated that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, the company plans to advance AVN-101 into clinical trials in the first quarter of 2009.
These studies have demonstrated that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, the company plans to advance AVN-101 into clinical trials in the first quarter of 2009.